GENETIC TESTING AND MOLECULAR BIOMARKERS
Volume 18, Number 11, 2014
ª Mary Ann Liebert, Inc.
Pp. 1–14
DOI: 10.1089/gtmb.2014.0109

ORIGINAL ARTICLE

The Use of Next-Generation Sequencing

in Molecular Diagnosis of Neuroﬁbromatosis Type 1:

A Validation Study

Ryo Maruoka,1,2 Toshiki Takenouchi,1,3 Chiharu Torii,1 Atsushi Shimizu,4 Kumiko Misu,1 Koichiro Higasa,5

Fumihiko Matsuda,5 Arihito Ota,6 Katsumi Tanito,6 Akira Kuramochi,7 Yoshimi Arima,8 Fujio Otsuka,9

Yuichi Yoshida,10 Keiji Moriyama,2 Michihito Niimura,6 Hideyuki Saya,8 and Kenjiro Kosaki1

Aims: We assessed the validity of a next-generation sequencing protocol using in-solution hybridization-based
enrichment to identify NF1 mutations for the diagnosis of 86 patients with a prototypic genetic syndrome,
neuroﬁbromatosis type 1. In addition, other causative genes for classic genetic syndromes were set as the target
genes for coverage analysis. Results: The protocol identiﬁed 30 nonsense, 19 frameshift, and 8 splice-site
mutations, together with 10 nucleotide substitutions that were previously reported to be pathogenic. In the
remaining 19 samples, 10 had single-exon or multiple-exon deletions detected by a multiplex ligation-
dependent probe ampliﬁcation method and 3 had missense mutations that were not observed in the normal
Japanese SNP database and were predicted to be pathogenic. Coverage analysis of the genes other than the NF1
gene included on the same diagnostic panel indicated that the mean coverage was 115-fold, a sufﬁcient depth
for mutation detection. Conclusions: The overall mutation detection rate using the currently reported method in
86 patients who met the clinical diagnostic criteria was 92.1% (70/76) when 10 patients with large deletions
were excluded. The results validate the clinical utility of this next-generation sequencing-based method for the
diagnosis of neuroﬁbromatosis type 1. Comparable detection rates can be expected for other genetic syndromes,
based on the results of the coverage analysis.

Introduction

G enetic testing has helped clinicians to deﬁne the

molecular pathology of diseases, especially when pa-
tients present with an atypical combination of phenotypic
features. Our group developed a custom-designed mutation
analysis panel using denaturing high-pressure liquid chro-
matography for the systematic screening of patients with
classic genetic syndromes (Kosaki et al., 2005). The system
can be used to screen all the exons of the candidate gene
quickly and has been helpful in conﬁrming the clinical di-
agnosis, as published in a series of reports in this journal

(Udaka et al., 2005, 2006, 2007; Aramaki et al., 2006; Sa-
mejima et al., 2007; Hattori et al., 2009). Nevertheless, the
throughput of the system was not high enough to screen
multiple candidate genes in a single testing.

The recent advent of a target sequencing panel with the
next-generation sequencing technology has enabled many
genes, regardless of size, to be analyzed in a systematic and
comprehensive manner, as reviewed in this journal (Yan
et al., 2013). The strength of such a comprehensive approach
is the ability to detect atypical presentations of classic syn-
dromes, as illustrated by our recent reports on several patients
with atypical presentations of mutations in the causative

1Center for Medical Genetics, Keio University School of Medicine, Tokyo, Japan.
2Section of Maxillofacial Orthognathics, Division of Maxillofacial/Neck Reconstruction, Department of Maxillofacial Reconstruction

and Function, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.

3Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
4Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, Japan.
5Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
6Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
7Department of Dermatology, Saitama Medical University, Saitama, Japan.
8Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
9Department of Dermatology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
10Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago,

Japan.

1

2

MARUOKA ET AL.

genes of three classic genetic syndromes: the neonatal pro-
geroid presentation of an FBN1 mutation (Takenouchi et al.,
2013a), the Noonan-cafe au lait syndrome-like presentation
of a MAP2K2 mutation (Takenouchi et al., 2013b), and
Stickler syndrome-like presentation of SOX9 mutation (Ta-
kenouchi et al., 2014).

In this study, we assessed the analytical and clinical
validity of the next-generation sequencing protocol with in-
solution hybridization-based enrichment to identify disease-
causing mutations in the diagnosis of a prototypic genetic
syndrome, neuroﬁbromatosis type 1, compared with direct
capillary sequencing, which is the current gold standard
methodology. The reason for the choice of the NF1 gene, the
causative gene for neuroﬁbromatosis type 1, was twofold:
(1) neuroﬁbromatosis type 1 is a relatively common genetic
condition with readily recognizable phenotypes: cafe´-au-lait
spots, cutaneous neuroﬁbromas, axillary and inguinal freck-
ling, and Lisch nodules (iris hamartomas) (Carey and Vis-
kochil, 1999) and (2) the NF1 gene comprised a total of 58
exons and is one of the largest genes in the human genome,
making it a relatively difﬁcult clinical target for direct cap-
illary sequencing.

Materials and Methods

Patients

The current research protocol was approved by the insti-
tutional review board of Keio University and each partici-
pating center. Eighty-six patients with neuroﬁbromatosis
type 1 who met the NIH clinical diagnostic criteria (Neuro-
ﬁbromatosis Conference Statement, 1988) were recruited
from multiple centers participating in the project. The NIH
diagnostic criteria for neuroﬁbromatosis type 1 deﬁnes an
individual as neuroﬁbromatosis type 1 when the person has
two or more of the following features: six or more cafe´-au-lait
macules with a maximum diameter of over 5 mm in prepu-
bertal individuals and with a maximum diameter of over
15 mm in postpubertal individuals; two or more neuroﬁbro-
mas of any type or 1 plexiform neuroﬁbroma; freckling in the
axillary or inguinal regions; optic glioma, two or more Lisch
nodules; a distinctive osseous lesion, such as sphenoid dys-
plasia or tibial pseudarthrosis; and a ﬁrst-degree relative
(parent, sibling, or offspring) with neuroﬁbromatosis type 1,
as deﬁned according to the above-mentioned criteria. After
written consent was obtained at each participating center, the
whole blood samples were sent to Keio University for genetic
analysis.

Genomic DNA, sample preparation, targeted
capturing, sequencing

Genomic DNA was extracted from peripheral blood ac-
cording to standard procedures using the phenol–chloroform
extraction method and checked for quality using Qubit (Life
Technologies). The genomic DNA (3 mg) was fragmented
into *150 bp. In-solution hybridization-based enrichment
was performed using the SureSelect Target Enrichment
system (Agilent Technologies). The NF1 gene (the canonical
Refseq transcript NM_001042492.2)
together with 108
causative genes for the more common classical congenital
malformation syndromes selected from a standard textbook
( Jones, 2005) was set as the target gene (Table 1). Genes that

are responsible for a disease phenotype and involved in the
RAS pathway (i.e., Rasopathy genes) (Aoki et al., 2008) were
included in the 108 genes set. A biotinylated RNA capture
library was designed using the eArray system (Agilent
Technologies) according to the manufacturer’s protocol. The
captured DNA was subjected to a 150-bp paired-end read
sequencing on the MiSeq system (Illumina).

Bioinformatics pipeline

The sequence reads from the sequencer were exported as
FASTQ format ﬁles and were analyzed using sets of open-
source programs by means of the default parameters; the
sequence reads were aligned to the human reference genome
DNA sequence (hs37d5 assembly) using the Burrows–
Wheeler Alignment (BWA) tool version 0.6.1 (Li and Dur-
bin, 2009). The Genome Analysis Toolkit (GATK) package
(McKenna et al., 2010) was used to perform local realign-
ment, base quality score recalibration, and SNP/indel calls.
The called SNPs/indels were annotated using snpEff version
3.1 (Cingolani et al., 2012), regarded as nonpathogenic, and
excluded from further analysis when they were observed in
the 1000 Genomes Project (www.1000genomes.org/) or in
the Japanese SNP dataset of 1208 normal individuals ( Jap-
anese Genetic Variation Consortium, 2013). The variants and
alignments were visually inspected using the Integrative
Genomics Viewer version 2.1 (Thorvaldsdo´ttir et al., 2013)
and VarSifter version 1.5 (Teer et al., 2012). Variants in the
including PTPN11, KRAS, SOS1, RAF1,
RAS pathway,
SHOC2, HRAS, BRAF, MAPK1, MAP2K1, MAP2K2,
MAPK3, SPRED1, and RASA1, were evaluated for pathoge-
nicity. Other genes were not subject to further variant analysis
to avoid potential issues with incidental ﬁndings. A statistical
coverage analysis was performed as described below.

Coverage analysis

Information about enrichment performance and target
coverage was obtained using the software NGSrich version
0.7.8 (Frommolt et al., 2012). The following parameters were
measured: information about the number of reads, mean
coverage, fraction of the target region with a particular depth
across the 109 genes, information on the number of genes that
are poorly covered, and a summary table with exon-speciﬁc
coverage information at the NF1 locus.

Direct capillary sequencing for validation

When the next-generation sequencing protocol identiﬁed
truncating mutations, including nonsense mutations, frame-
shift mutations, and mutations at the canonical splice sites, or
missense mutations that had been previously reported as
being pathogenic in the literature, the variants were validated
with direct capillary sequencing. In the remaining samples,
all the exons were analyzed using direct capillary sequencing
(Richards et al., 2008). For direct capillary sequencing, 56
pairs of polymerase chain reaction (PCR) primers were de-
signed on ﬂanking intronic and untranslated regions to en-
compass the coding regions of the 58 NF1 exons and at least
30 bp of the intronic sequence surrounding each exon (Table
2). Three primers were designed newly using primer design
software, Primer3 (Rozen and Skaletsky, 2000), and the re-
maining primers were described elsewhere (Purandare et al.,

,
e
m
o
r
d
n
y
s

l
a
e
n
o
r
e
p
o
l
u
p
a
c
S

9
6
8

,

4
0
9

,

3
2
–
6
4
9
1
8
8
3
2

,

,

e
s
a
e
s
i
D

n
o
i
t
i
s
o
p

r
i
a
p
e
s
a
B

)
7
3
h
C
R
G

(

e
m
o
r
d
n
y
s

p
o
k
t
i

W

2
6
6
5
6
8

,

,

4
–
1
9
3
1
6
8

,

,

4

1

e
p
y
t

s
i
s
o
t
a
m
o
r
b
ﬁ
o
r
u
e
N

e
p
y
t

c
i
h
t
a
p
o
y
m

e
m
o
r
d
n
y
s

r
e
n
t
h
c
e
F

,

,

6
0
1
4
8
7
6
3
–
2
2
3
7
7
6
6
3

,

,

,

,

4
9
6
4
0
7
9
2
–
4
4
9
1
2
4
9
2

,

,

e
m
o
r
d
n
y
s

e
g
n
a
L
e
d

a
i
l
e
n
r
o
C

5
2
9

,

5
6
0

,

7
3
–
0
6
8
6
7
8

,

,

6
3

e
m
o
r
d
n
y
s

e
l
l
i
g
a
l
A

9
7
8
9
3
6

,

,

e
m
o
r
d
n
y
s

n
a
n
o
o
N

4
1
5
9
5
2

,

,

0
2
1
–
5
7
1
4
5
4
0
2
1

,

,

5
1
1
–
4
8
0
7
4
2
5
1
1

,

,

e
m
o
r
d
n
y
s

n
o
i
t
a
l
i
t
n
e
v
o
p
y
h

a
i
m
l
a
h
t
h
p
o
r
c
i
m
c
i
m
o
r
d
n
y
S

l
a
r
t
n
e
c

l
a
t
i
n
e
g
n
o
C

e
s
a
e
s
i
d

g
n
u
r
p
s
h
c
s
r
i

H

e
m
o
r
d
n
y
s

s
o
t
o
S

,

,

3
1
2
7
2
7
6
7
1
–
5
2
0
0
6
5
6
7
1

,

,

,

3
9
1
7
7
2
7
5
–
4
2
4

,

,

7
6
2
7
5

,

,

,

4
3
3
8
2
8
5
–
7
1
8
3
2
8
5

,

,

,

,

6
8
9
0
5
7
1
4
–
8
9
0
6
4
7
1
4

,

,

d
n
a

y
e
n
d
i
k

c
i
t
s
y
c
y
l
o
P

2
2
4

,

2
5
9

,

1
5
–
4
4
1

,

0
8
4

,

1
5

e
m
o
r
d
n
y
s

s
u
v
e
n

l
l
e
c

l
a
s
a
B

e
m
o
r
d
n
y
s

s
o
l
n
a
D
-
s
r
e
l
h
E

e
s
a
e
s
i
d

s
’
g
n
u
r
p
s
h
c
s
r
i

H

e
m
o
r
d
n
y
s
D
R
A
P
O
E
L

e
g
n
a
L

e
d

a
i
l
e
n
r
o
C

e
s
a
e
s
i
d

c
i
t
a
p
e
h

e
m
o
r
d
n
y
s

r
e
b
e
W

s
e
k
r
a
P

e
m
o
r
d
n
y
s
D
R
A
P
O
E
L

e
m
o
r
d
n
y
s

,

,

8
9
5
5
3
0
2
1
–
3
2
7
4
9
9
1
1

,

,

,

,

9
5
8
5
7
3
6
–
4
0
3
5
7
3
6

,

,

,

,

6
4
2
9
7
2
8
9
–
3
6
2
5
0
2
8
9

,

,

,

,

6
1
7
7
4
9
2
1
1
–
5
3
5

,

6
5
8

,

2
1
1

,

,

4
0
1
7
8
8
7
1
1
–
2
7
1
8
5
8
7
1
1

,

,

9
9
6

,

5
0
7

,

2
1
–
9
9
0
5
2
6

,

,

2
1

,

,

2
4
7
7
8
6
6
8
–
9
6
0
4
6
5
6
8

,

,

I
I

N
E
M

8
9
7

,

5
2
6

,

3
4
–
6
1
5
2
7
5
3
4

,

,

e
m
o
r
d
n
y
s

y
a
r

l
a
i
d
a
r
-
e
n
a
u
D

e
m
o
r
d
n
y
s

s
k
c
o
r
B
–
s
e
n
w
o
T

a
i
s
a
l
p
s
y
d

l
a
i
n
a
r
c
o
d
i
e
l
C

e
m
o
r
d
n
y
s

a
d
a
g
u
r

B

e
m
o
r
d
n
y
s

e
k
i
l
-
n
a
n
o
o
N

y
l
a
h
p
e
c
n
e
s
o
r
p
o
l
o
H

,

,

8
1
8
8
1
5
5
4
–
3
5
0
6
9
2
5
4

,

,

2
8
1
5
8
1

,

,

1
5
–
5
8
8
9
6
1
1
5

,

,

8
5
0

,

9
1
4

,

0
5
–
0
5
5
0
0
4
0
5

,

,

,

,

2
5
3
1
3
5
5
3
–
4
5
5
1
2
5
5
3

,

,

,

,

6
6
9
4
0
6
5
5
1
–
7
5
5

,

5
9
5

,

5
5
1

,

,

4
2
4
3
7
7
2
1
1
–
0
0
3
9
7
6
2
1
1

,

,

)
d
e
u
n
i
t
n
o
c
(

y
l
a
h
p
e
c
n
e
s
o
r
p
o
l
o
H

5
1
2

,

3
7
1

,

5
4
–
6
3
0
9
6
1

,

,

5
4

4

4
1

2
2

7
1

5

1

1

9
1

5

4
1

4

6

1

9
1

9

2
1

8

3

5

0
1

6

6
1

0
2

9
1

7

2

0
1

e
m
o
s
o
m
o
r
h
C

e
n
e
G

e
s
a
e
s
i
D

s
e
n
e
G
9
0
1

e
h
t

f
o

t
s
i
L

.

1

e
l
b
a
T

n
o
i
t
i
s
o
p

r
i
a
p
e
s
a
B

)
7
3
h
C
R
G

(

6
4
1
,
1
5
7
0
9
–
0
3
8

,

,

4
9
6

,

0
9

1
X
S
M

7
H
Y
M

9
H
Y
M

1
F
N

n
o
i
t
c
n
u
f
s
y
d

e
l
c
s
u
m

h
t
o
o
m

s

c
i
m
e
t
s
y
s
i
t
l
u
M

e
m
o
r
d
n
y
s

c
i
g
a
h
r
r
o
m
e
h

y
r
a
t
i
d
e
r
e
H

4
4
1
,
7
1
3
2
5
–
6
5
6

,

,

0
0
3

,

2
5

t
c
e
f
e
d

l
a
t
p
e
s

l
a
i
r
t

A

6
2
9
,
7
8
0
5
3
–
6
9
2

,

,

0
8
0

,

5
3

a
i
s
a
t
c
e
i
g
n
a
l
e
t

s
u
o
e
n
a
t
u
c
o
i
c
a
f
o
i
d
r
a
C

3
6
5

,

e
m
o
r
d
n
y
s

,

4
2
6
0
4
1
–
8
4
7
5
1
4
0
4
1

,

,

2
H
C
T
O
N

e
k
i
l
-
e
m
o
r
d
n
y
s

n
a
m
l
e
g
n
A

8
4
7

,

r
e
d
r
o
s
i
d

,

1
7
6
8
1
–
4
2
7
3
4
4

,

,

8
1

L
B
P
I
N

e
k
i
l
-
e
m
o
r
d
n
y
s

n
a
n
o
o
N

8
5
8

,
8
7
1

,

9
1
1
–
5
8
9

,

6
7
0
9
1
1

,

S
A
R
N

N
T
R
N

1
D
S
N

2
X
T
O

B
2
X
O
H
P

1
D
H
K
P

1
D
O
L
P

N
P
S
P

1
1
N
P
T
P

1
H
C
T
P

1
2
D
A
R

1
A
S
A
R

1
F
A
R

T
E
R

2
X
N
U
R

1
L
L
A
S

4
L
L
A
S

B
1
N
C
S

2
C
O
H
S

3
X
I
S

H
H
S

a
t
c
e
f
r
e
p
m

i

s
i
s
e
n
e
g
o
e
t
s
O

e
m
o
r
d
n
y
s

s
o
l
n
a
D
-
s
r
e
l
h
E

e
m
o
r
d
n
y
s

E
G
R
A
H
C

s
i
s
e
n
e
g
o
r
d
n
o
h
c
o
r
b
i
F

e
m
o
r
d
n
y
s

r
e
l
k
c
i
t
S

r
e
d
r
o
s
i
d

1
5
0

,

,

4
7
5
3
0
1
–
2
2
0
2
4
3
3
0
1

,

,

6
8
5
0
8
7

,

,

1
6
–
0
2
3

,

1
9
5
1
6

,

4
4
2
0
6
1

,

,

3
3
–
8
6
4

,

0
3
1
3
3

,

2
0
0
,
9
7
2
8
4
–
6
5
4

,

,

1
6
2

,

8
4

3
4
5
0
6
0

,

,

4
9
–
2
7
8

,

3
2
0
4
9

,

e
m
o
r
d
n
y
s

r
e
l
k
c
i
t
S

4
8
2
,
8
9
3
8
4
–
7
4
7

,

,

6
6
3

,

8
4

e
m
o
r
d
n
y
s

i
b
y
a
T
-
n
i
e
t
s
n
i
b
u
R

0
2
1
0
3
9

,

,

3
–
4
5
0
5
7
7
3

,

,

e
m
o
r
d
n
y
s

M
-
3

2
8
6
1
2
0

,

,

3
4
–
4
5
3

,

5
0
0
3
4

,

a
i
s
a
l
p
s
y
d

l
a
e
s
y
h
p
i
p
E

3
1
1
,
2
0
9
8
1
–
2
8
5

,

,

3
9
8

,

8
1

e
m
o
r
d
n
y
s

e
m
o
r
d
n
y
s

r
e
l
k
c
i
t
S

r
e
l
k
c
i
t
S

5
8
7
2
1
0

,

,

1
7
–
2
4
7

,

5
2
9
0
7

,

8
3
9
2
8
7

,

,

0
4
–
1
6
1

,

6
6
7
0
4

,

e
m
o
r
d
n
y
s

n
o
i
t
a
l
i
t
n
e
v
o
p
y
h

l
a
r
t
n
e
C

e
s
a
e
s
i
d

g
n
u
r
p
s
h
c
s
r
i

H

3
3
0
2
7
6

,

,

1
2
–
9
3
7

,

3
4
5
1
2

,

6
4
0
,
1
0
9
7
5
–
8
9
4

,

,

5
7
8

,

7
5

e
m
o
r
d
n
y
s

g
r
u
b
n
e
d
r
a
a

W

3
6
6
,
9
4
5
8
7
–
5
1
6

,

,

9
6
4

,

8
7

s
t
n
e
m
e
v
o
m

r
o
r
r
i

M

a
m
o
t
s
a
l
b
o
l
l
u
d
e
M

2
7
2
2
6
0

,

,

1
5
–
1
4
5
6
6
8
9
4

,

,

6
2
5

,

,

9
0
2
1
4
–
0
6
5
2
9
1

,

,

1
4

a
i
s
a
l
p
s
y
d

l
a
s
a
n
o
t
n
o
r
f
o
i
n
a
r
C

6
0
0

,

,

2
6
0
8
6
–
9
3
8
8
4
0

,

,

8
6

e
m
o
r
d
n
y
s

e
m
o
r
d
n
y
s

e
m
o
r
d
n
y
s

s
o
l
n
a
D
-
s
r
e
l
h
E

s
o
l
n
a
D
-
s
r
e
l
h
E

s
o
l
n
a
D
-
s
r
e
l
h
E

1
7
4

,

8
8
6

,

,

7
7
8
9
8
1
–
8
9
0
9
3
8
9
8
1

,

,

,

6
3
7
7
3
1
–
0
5
6
3
3
5
7
3
1

,

,

7
6
6

,

,

4
4
0
0
9
1
–
0
4
6
6
9
8
9
8
1

,

,

a
i
s
a
t
c
e
i
g
n
a
l
e
t

c
i
g
a
h
r
r
o
m
e
h

y
t
i
d
e
r
e
H

1
5
0

,

,

7
1
6
0
3
1
–
0
9
2
7
7
5
0
3
1

,

,

e
m
o
s
o
m
o
r
h
C

e
n
e
G

0
1

5
1

2
1

7

1
1

X

8

1

6

7

7
1

2
1

2

9

2

6

1

9
1

6
1

6

8
1

X

1

0
2

3
1

X

9

1
C
T
C
A

1
L
R
V
C
A

F
A
R
B

L
B
C

1
A
1
1
L
O
C

2
A
1
1
L
O
C

1
A
1
L
O
C

2
A
1
L
O
C

7
D
H
C

5
L
K
D
C

2
A
T
C
A

1
A
2
L
O
C

1
A
3
L
O
C

1
A
5
L
O
C

2
A
5
L
O
C

1
A
9
L
O
C

2
A
9
L
O
C

P
B
B
E
R
C

P
M
O
C

X
3
X
D
D

1
E
C
E

3
N
D
E

7
L
U
C

C
C
D

B
R
N
D
E

1
B
N
F
E

G
N
E

3

e
m
o
r
d
n
y
s

e
g
n
a
L
e
d

a
i
l
e
n
r
o
C

e
m
o
r
d
n
y
s

e
g
n
a
L
e
d

a
i
l
e
n
r
o
C

h
t
i

w
a
i
m
l
a
h
t
h
p
o
r
c
i
M

t
c
a
r
a
t
a
c

,

,

4
2
5
8
7
9
0
6
–
7
3
9
5
7
9
0
6

,

,

,

,

6
7
6
9
4
4
3
5
–
9
6
0
1
0
4
3
5

,

,

,

,

1
9
3
4
6
3
2
1
1
–
8
4
4
7
2
3
2
1
1

,

,

e
m
o
r
d
n
y
s

n
a
n
o
o
N

5
8
6

,

7
4
3

,

9
3
–
9
8
6
8
0
2

,

,

9
3

e
m
o
r
d
n
y
s
H
W
C
P

5
5
5

,

0
8
3

,

8
3
–
8
1
3
8
6
3
8
3

,

,

a
i
m
l
a
h
t
h
p
o
r
c
i
m
c
i
m
o
r
d
n
y
S

e
m
o
r
d
n
y
s

s
u
i
g
e
L

y
l
a
h
p
e
c
n
e
s
o
r
p
o
l
o
H

,

,

3
2
2
2
3
4
1
8
1
–
1
1
7
9
2
4
1
8
1

,

,

,

,

9
4
4
9
4
6
8
3
–
4
2
9
4
4
5
8
3

,

,

,

5
8
0
5
1
9
0
8
–
0
1
1

,

,

0
1
9
0
8

,

e
m
o
r
d
n
y
s

e
g
n
a
L
e
d

a
i
l
e
n
r
o
C

0
2
2
1
7
4

,

,

6
3
1
–
7
7
0
5
5
0
6
3
1

,

,

e
m
o
r
d
n
y
s

h
t
r
a
B

,

,

4
6
0
0
5
6
3
5
1
–
6
7
8

,

9
3
6

,

3
5
1

e
m
o
r
d
n
y
s

n
o
s
k
c
i
r
E
-
o
z
z
u
r
b
A

7
6
2

,

,

7
8
2
9
7
–
4
5
2

,

0
7
2

,

9
7

e
m
o
r
d
n
y
s

m
a
r
O

-
t
l
o
H

,

,

6
4
2
6
4
8
4
1
1
–
4
3
7
1
9
7
4
1
1

,

,

e
m
o
r
d
n
y
s

s
n
i
k
p
o
H

-
t
t
i
P

1
5
2

,

3
0
3

,

3
5
–
1
6
5
9
8
8
2
5

,

,

e
m
o
r
d
n
y
s

s
n
i
l
l
o
C

r
e
h
c
a
e
r
T

e
m
o
r
d
n
y
s

z
t
e
i
D
-
s
y
e
o
L

e
m
o
r
d
n
y
s

z
t
e
i
D
-
s
y
e
o
L

y
l
a
h
p
e
c
n
e
s
o
r
p
o
l
o
H

y
l
a
h
p
e
c
n
e
s
o
r
p
o
l
o
H

s
i
s
o
r
e
l
c
s

s
i
s
o
r
e
l
c
s

m

s
i
n
a
n

y
e
r
b
i
l
u
M

s
u
o
r
e
b
u
T

s
u
o
r
e
b
u
T

e
m
o
r
d
n
y
s

C
E
E

,

,

0
7
8
9
7
7
9
4
1
–
1
0
2
7
3
7
9
4
1

,

,

,

,

3
7
4
6
1
9
1
0
1
–
1
1
4

,

7
6
8

,

1
0
1

,

,

7
6
0
5
1
6
9
8
1
–
1
4
9

,

8
4
3

,

9
8
1

8
0
4

,

,

8
5
4
3
–
4
2
9

,

1
1
4

,

3

2
3
4

,

6
2
5

,

5
4
–
5
0
2
2
3
4
5
4

,

,

5
6
2
4
8
1

,

,

7
5
–
8
9
9
9
5
0
7
5

,

,

,

,

3
9
0
0
2
8
5
3
1
–
4
3
7

,

6
6
7

,

5
3
1

,

,

3
3
6
5
3
7
0
3
–
3
9
9
7
4
6
0
3

,

,

,

,

2
1
7
8
3
1
2
–
1
7
4
7
9
0
2

,

,

e
m
o
r
d
n
y
s

n
e
z
t
o
h
C

e
r
h
t
e
a
S

4
9
2

,

7
5
1

,

9
1
–
4
1
3

,

9
3
0

,

9
1

u
a
d
n
i
L
-
l
e
p
p
i
H
n
o
V

3
5
3

,

5
9
1

,

0
1
–
8
1
3

,

3
8
1

,

0
1

e
m
o
r
d
n
y
s

n
o
s
l
i

W

-
t
a
w
o
M

y
l
a
h
p
e
c
n
e
s
o
r
p
o
l
o
H

a
i
m
l
a
h
t
h
p
o
r
c
i
M

e
m
o
r
d
n
y
s

,

,

7
5
9
7
7
2
5
4
1
–
1
4
9

,

1
4
1

,

5
4
1

,

0
4
4
9
2
7
4
7
–
4
7
1

,

,

6
0
7
4
7

,

,

,

8
1
0
9
3
6
0
0
1
–
5
2
0
4
3
6
0
0
1

,

,

4
1

X

0
1

2

2
2

3

5
1

3
1

3

X

X

2
1

8
1

5

9

3

8
1

3

1
2

7
1

9

6
1

7

3

2

4
1

3
1

A
1
C
M
S

3
C
M
S

1
S
O
S

1
D
E
R
P
S

0
1
X
O
S

2
X
O
S

2
Y
R
P
S

1
G
A
T
S

2
2
X
B
T

5
X
B
T

Z
A
T

1
R
B
F
G
T

1
F
O
C
T

4
F
C
T

2
R
B
F
G
T

1
F
I
G
T

l
a
r
u
t
c
a
r
t
n
o
c

l
a
t
i
n
e
g
n
o
C

4
3
7

,

,

3
7
8
7
2
1
–
0
0
6
3
9
5
7
2
1

,

,

e
m
o
r
d
n
y
s

r
e
l
x
i
B
-
y
e
l
t
n
A

1
7
9

,
7
5
3

,

3
2
1
–
3
4
8

,

7
3
2
3
2
1

,

y
l
y
t
c
a
d
o
n
h
c
a
r
a

c
i
p
o
r
t
o
d
a
n
o
g
o
p
y
H

m

s
i
d
a
n
o
g
o
p
y
h

1
5
3
6
2
3

,

,

8
3
–
5
5
6

,

8
6
2
8
3

,

n
o
i
t
a
l
i
t
n
e
v
o
p
y
h

l
a
r
t
n
e
C

1
8
7
9
3
8

,

,

7
3
–
8
7
7

,

2
1
8
7
3

,

e
m
o
r
d
n
y
s

e
s
a
e
s
i
d

e
s
a
e
s
i
d

s
’
g
n
u
r
p
s
h
c
s
r
i

H

s
’
g
n
u
r
p
s
h
c
s
r
i

H

5
2
1

,
3
3
0

,

8
1
1
–
5
3
4

,

6
1
8
7
1
1

,

1
9
3
2
7
6

,

,

1
2
–
9
2
5

,

9
4
5
1
2

,

a
i
s
a
l
p
o
r
d
n
o
h
c
A

,

8
9
5
0
1
8
1
–
8
3
0

,

,

5
9
7
1

,

a
i
s
a
l
p
s
y
d

c
i
r
c
i
m
o
r
c
A

4
8
9
,
7
3
9
8
4
–
2
0
5

,

,

0
0
7

,

8
4

e
m
o
r
d
n
y
s

e
d
u
o
W

e
m
o
r
d
n
y
s

r
e
d

n
a
V

e
l
l
i
g
a
l
A

n
e
s
l
e
i
N
-
e
g
n
a
L

d
n
a

l
l
e
v
r
e
J

e
m
o
r
d
n
y
s

e
m
o
r
d
n
y
s

o
l
l
e
t
s
o
C

l
a
r
o
m
e
f
o
t
i
p
a
c
o
r
c
A

e
s
a
e
s
i
d

y
r
b
a
F

a
i
s
a
l
p
s
y
d

,

,

0
0
0
3
6
6
0
0
1
–
8
7
7

,

,

2
5
6
0
0
1

0
6
5

,

5
3
5
–
1
4
2
2
3
5

,

7
3
2

,

,

5
2
9
9
1
2
–
1
4
1
9
1
9
9
1
2

,

,

9
1
5

,

,

9
7
9
9
0
2
–
7
6
9
8
5
9
9
0
2

,

,

3
9
6
,
4
5
6
0
1
–
1
3
3

,

,

8
1
6

,

0
1

2
7
5
,
4
8
8
5
3
–
9
0
9

,

,

0
9
7

,

5
3

e
m
o
r
d
n
y
s

n
e
s
l
e
i
N
-
e
g
n
a
L

d
n
a

l
l
e
v
r
e
J

9
3
3
0
7
8

,

,

2
–
0
2
2
6
6
4
2

,

,

e
m
o
r
d
n
y
s

n
e
s
r
e
d
n
A

8
8
1
,
6
7
1
8
6
–
6
5
7

,

,

4
6
1

,

8
6

0
1
C
P
P
A
R
T

7
3
M
I
R
T

1
T
S
I
W
T

1
C
S
T

2
C
S
T

L
H
V

2
X
S
V

2
B
E
Z

2
C

I
Z

e
m
o
r
d
n
y
s

n
o
l
o
c
a
g
e
m

n
o
l
o
c
a
g
e
M

4
3
2

,
7
4
6

,

4
0
1
–
9
5
0

,

5
0
6
4
0
1

,

s
u
o
e
n
a
t
u
c
o
i
c
a
f
o
i
d
r
a
C

1
8
8
,
3
8
7
6
6
–
1
8
1

,

,

9
7
6

,

6
6

e
m
o
r
d
n
y
s

n
a
n
o
o
N

e
m
o
r
d
n
y
s
H
S
A
R
C

e
s
a
e
s
i
d

n
o
n
a
D

,

,

7
2
6
1
5
1
3
5
1
–
8
6
9

,

,

6
2
1
3
5
1

9
6
8
,
3
0
4
5
2
–
9
7
1

,

,

8
5
3

,

5
2

,

,

3
0
2
3
0
6
9
1
1
–
2
0
0

,

,

0
6
5
9
1
1

e
m
o
r
d
n
y
s

e
m
o
r
d
n
y
s

s
u
o
e
n
a
t
u
c
o
i
c
a
f
o
i
d
r
a
C

5
2
1
4
2
1

,

,

4
–
8
1
3
0
9
0
4

,

,

a
i
s
a
l
p
s
y
d

c
i
l
e
m
o
s
e
m
o
r
c
A

y
h
p
o
r
t
r
e
p
y
h

c
a
i
d
r
a
C

9
6
9
,
1
2
2
2
2
–
5
4
9

,

,

3
1
1

,

2
2

9
2
6
,
4
3
1
0
3
–
5
2
4

,

,

5
2
1

,

0
3

e
m
o
r
d
n
y
s

t
t
e
R

,

,

7
8
1
3
6
3
3
5
1
–
4
2
0

,

7
8
2
3
5
1

,

3
6
P
T

n
e
z
t
n
i
r
p
h
S
-
g
r
e
b
d
l
o
G

8
3
7
,
6
7
7
0
7
–
6
7
4

,

,

8
4
7

,

0
7

e
m
o
r
d
n
y
s

B
B
B
G
z
t
i
p
O

8
2
8

,

,

1
5
8
0
1
–
9
4
3
3
1
4

,

,

0
1

6
X
I
S

e
m
o
r
d
n
y
s

i
b
y
a
T
-
n
i
e
t
s
n
i
b
u
R

0
8
0
,
6
7
5
1
4
–
3
1
6

,

,

8
8
4

,

1
4

2
2

5
1

5

8

4

5

0
1

0
1

8

X

1
1

2

1

0
2

1
2

7
1

1
1

0
1

4
1

2
1

X

X

5
1

9
1

2
2

6
1

X

X

0
0
3
P
E

1
N
B
F

2
N
B
F

1
R
F
G
F

2
R
F
G
F

3
R
F
G
F

F
N
D
G

1
A
R
F
G

2
A
R
F
G

S
A
R
H

A
L
G

H
H

I

1
E
N
C
K

6
F
R
I

1
G
A
J

2
J
N
C
K

1
Q
N
C
K

9
7
2
1
A
A
I

K

A
6
2
F
I

K

M
A
C
1
L

2
P
M
A
L

S
A
R
K

1
K
2
P
A
M

2
K
2
P
A
M

1
K
P
A
M

3
K
P
A
M

2
P
C
E
M

1
D
M

I

4

)
d
e
u
n
i
t
n
o
C

(

.

1

e
l
b
a
T

e
s
a
e
s
i
D

n
o
i
t
i
s
o
p

r
i
a
p
e
s
a
B

)
7
3
h
C
R
G

(

e
m
o
s
o
m
o
r
h
C

e
n
e
G

e
s
a
e
s
i
D

n
o
i
t
i
s
o
p

r
i
a
p
e
s
a
B

)
7
3
h
C
R
G

(

e
m
o
s
o
m
o
r
h
C

e
n
e
G

e
c
n
e
r
e
f
e
R

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

t
r
o
p
e
r

s
i
h
T

)
5
9
9
1
(

.
l
a

t
e

e
r
a
d
n
a
r
u
P

)
5
9
9
1
(

.
l
a

t
e

e
r
a
d
n
a
r
u
P

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
1
0
0
2
(

.
l
a

t
e

n
a
H

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
d
e
u
n
i
t
n
o
c
(

e
z
i
s

1
8
1

7
2
3

0
0
4

6
2
2

5
9
1

8
9
2

8
9
2

6
9
2

4
4
6

7
6
4

1
2
3

4
2
4

8
9
2

5
1
4

7
0
5

n
o
c
i
l
p
m
A

s
r
e
m
i
r
P

n
o
i
t
c
a
e
R
n
i
a
h
C

e
s
a
r
e
m
y
l
o
P

f
o

t
s
i
L

.

2

e
l
b
a
T

T
T
T
C
T
T
C
C
T
A
G
A
T
C
G
A
C
G
A
C
T
A
C
C

G
T
C
T
G
T
A
A
T
T
C
G
G
T
T
C
A
C
G
T
T
G
C

C
A
A
A
T
A
A
T
A
T
G
G
A
C
G
A
G
G
T
A
T
A

G
T
G
T
A
T
C
T
T
G
G
C
G
A
C
A
A
A
A

C
T
A
T
T
A
G
A
T
C
G
A
T
A
G
A
A
T
T
T
A
A
G

G
T
C
T
A
A
T
A
A
A
T
A
A
C
A
T
A
C
T
T
C
A
G

C
A
A
C
G
A
G
A
C
A
A
A
C
T
T
A
G
T
T
T
A
T

A
T
T
G
A
T
T
C
T
A
A
T
G
T
T
T
A
T
A
C
C
T
C

C
C
C
T
A
T
C
A
C
T
T
G
T
G
A
G
A
G
G

C
C
T
C
A
A
C
T
C
T
T
A
A
C
T
C
A
T
A
T
T
C

A
C
G
A
C
A
A
A
C
A
A
T
T
C
T
T
A
T
A
G

C
C
G
A
T
A
C
T
T
A
G
T
G
T
C
T
T
T
T

G
A
T
G
T
G
T
A
A
A
G
A
A
A
T
T
G
A
A
C
A
T
T
G

C
A
A
A
C
G
G
T
G
G
T
C
C
G
G
T
G
A
A
C
A
A
T
C

T
T
C
A
G
A
T
A
T
T
A
A
C
C
T
A
T
T
T
G
T
T
A
T
T
T

C
A
A
A
A
A
G
G
G
T
C
A
A
C
T
G
A
A
T
T
G
T
C
C
T

T
T
G
T
T
A
A
G
A
A
G
T
T
T
C
A
G
A
C
C
T
A
A
G
T

T
G
A
T
C
T
G
A
T
A
T
A
G
G
A
C
C
G
G
A
G
G
G
A
T
C

T
T
T
G
C
A
T
A
A
A
A
A
G
G
A
A
T
A
T
C
A
A
G
G
T
T

A
G
A
T
T
C
T
C
T
T
A
A
G
T
T
T
C
T
T
T
T
G
G
G
A

G
T
T
A
C
T
T
T
T
A
G
T
G
T
A
G
T
T
G
T
T
A
A
T
A

A
G
A
T
T
T
T
C
C
G
A
G
G
T
C
T
T
T
G
G
T
T
G
G

A
G
T
C
A
A
A
C
T
A
A
A
C
C
C
C
A
A
A
C
A
A
C

A
T
G
A
A
G
T
G
G
A
C
T
A
G
T
T
A
T
A
T
C
T
A
A
T
A

C
T
A
T
G
T
A
A
C
A
T
A
A
T
T
A
C
G
A
G
G
A
A
C
G

C
G
A
A
T
T
T
A
T
T
T
T
T
G
T
G
A
A
C
G
T
A
C
C

T
A
G
T
A
G
T
C
C
T
C
C
A
A
A
A
A
A
C
A
A
A
A
C

T
G
T
A
C
C
C
T
G
A
G
T
T
T
C
A
A
A
A
T
C
G
T
G

A
A
G
T
A
A
C
C
T
T
G
T
C
G
G
A
T
T
A
G
T
T

G
A
G
A
A
G
T
A
G
A
C
C
A
A
G
T
T
T
T
A
A

9
2

0
3

1
3

2
3

3
3

4
3

5
3

6
3

7
3

8
3

9
3

0
4

1
4

2
4

3
4

)
5
9
9
1
(

.
l
a

t
e

e
r
a
d
n
a
r
u
P

)
5
9
9
1
(

.
l
a

t
e

e
r
a
d
n
a
r
u
P

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
1
0
0
2
(

.
l
a

t
e

n
a
H

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
1
0
0
2
(

.
l
a

t
e

n
a
H

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
1
0
0
2
(

.
l
a

t
e

n
a
H

)
5
9
9
1
(

.
l
a

t
e

e
r
a
d
n
a
r
u
P

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
1
0
0
2
(

.
l
a

t
e

n
a
H

t
r
o
p
e
r

s
i
h
T

)
¢

3
-
¢
5
(

e
c
n
e
u
q
e
s

r
e
m
i
r
P

n
o
x
E

e
c
n
e
r
e
f
e
R

n
o
c
i
l
p
m
A

e
z
i
s

9
3
4

8
3
4

5
4
2

7
1
5

5
1
2

8
0
3

1
1
2

1
0
3

8
2
3

3
7
2

4
6
2

2
2
2

3
0
4

5
7
2

6
5
2

C
G
A
C
C
C
A
A
A
A
T
C
T
A
A
G
T
C
A
C
T
C
G

G
T
T
G
T
G
T
G
T
A
G
A
C
T
T
T
T
C
A
C
T
T
T

G
A
A
C
G
G
T
A
A
C
T
T
T
T
A
G
T
A
C
T
G
C

T
T
C
T
C
C
G
T
T
C
C
T
C
T
C
C
C
A
G
A
C

G
T
C
G
G
A
G
G
C
T
G
G
G
A
G
G
T
A
G
G

A
A
T
C
C
C
C
T
G
T
C
C
A
C
A
C
C
A
T
A
G
A
G

A
G
A
C
T
T
T
T
T
T
T
A
G
T
G
A
C
C
C
A
G
T
T

A
G
C
T
A
T
C
A
A
C
A
G
A
C
G
A
T
C
C
T
T
T

T
A
A
A
C
G
A
C
A
A
C
A
A
T
C
G
T
A
G
G
A

G
T
G
T
T
T
G
A
A
G
A
T
T
G
A
A
G
G
A
A
G

A
G
A
A
A
A
T
T
T
A
C
G
G
A
T
G
A
A
C
A
C

G
T
T
T
C
A
T
G
T
C
T
A
C
A
C
C
T
G
G
T

T
G
T
G
T
G
G
T
G
G
A
T
C
T
A
A
A
T
T

G
A
G
G
T
C
T
C
T
T
T
A
C
T
C
A
A
A

C
C
G
T
T
G
T
A
A
A
A
A
T
T
T
T
C
T
A
T
T
T
G
T
A
C

C
C
T
C
C
C
G
T
T
T
T
A
A
T
A
A
A
G
G
T
A
A
T
A

C
G
A
T
T
A
T
A
A
T
A
T
C
G
T
T
T
A
A
T
T
G
T
C

C
T
T
A
A
A
A
G
A
T
C
G
T
A
T
T
C
A
T
A
A
T
A
C

G
T
A
C
A
T
T
A
T
T
G
T
A
G
T
T
G
T
G
T
A
A
T
G

A
C
A
A
T
A
G
G
A
A
A
T
A
T
T
T
G
T
T
T
T
T
C
T
G

G
G
T
T
T
T
T
C
T
T
G
T
C
G
T
T
T
A
T
C
T
T
T
C

A
C
G
T
G
A
G
A
A
C
C
A
A
A
A
G
T
T
T
T
T
C
C

C
C
T
T
C
T
T
T
T
T
C
A
T
G
T
T
T
T
A
A
T
G
C
A

C
T
T
A
G
A
G
T
G
G
A
G
G
A
A
A
G
A
T
A
A
C

T
G
T
T
T
T
G
T
T
A
C
T
T
T
T
A
G
C
A
A
A
A
A
C
G

C
T
T
T
A
C
C
A
T
A
C
A
A
A
T
A
C
A
G
A
T
A
T
G

G
T
T
C
C
T
T
T
T
T
T
T
C
C
T
T
T
G
A
A
G
T
T
A

T
T
A
A
C
C
C
A
A
A
T
C
G
A
C
T
T
T
G
C
G

T
C
T
G
A
G
T
G
A
G
T
T
T
G
T
A
A
A
A
A
C
C

G
T
G
A
A
G
G
T
T
T
C
C
A
A
A
A
T
A
C
C
A

1

2

3

4

5

6

7

8

9

0
1

1
1

2
1

3
1

4
1

5
1

)
¢
3
-
¢
5
(

e
c
n
e
u
q
e
s

r
e
m
i
r
P

n
o
x
E

5

)
d
e
u
n
i
t
n
o
C

(

.

2

e
l
b
a
T

e
c
n
e
r
e
f
e
R

)
7
9
9
1
(

.
l
a

t
e

y
h
t
a
n
r
e
b
A

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
9
9
1
(

.
l
a

t
e

y
h
t
a
n
r
e
b
A

)
7
9
9
1
(

.
l
a

t
e

y
h
t
a
n
r
e
b
A

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
1
0
0
2
(

.
l
a

t
e

n
a
H

)
7
9
9
1
(

.
l
a

t
e

y
h
t
a
n
r
e
b
A

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
9
9
1
(

.
l
a

t
e

y
h
t
a
n
r
e
b
A

)
7
9
9
1
(

.
l
a

t
e

y
h
t
a
n
r
e
b
A

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

e
z
i
s

2
1
5

6
3
2

4
3
3

4
8
2

8
2
3

3
7
3

6
5
3

5
2
3

6
0
5

0
9
2

5
8
1

1
5
3

1
7
5

n
o
c
i
l
p
m
A

)
¢

3
-
¢
5
(

e
c
n
e
u
q
e
s

r
e
m
i
r
P

n
o
x
E

e
c
n
e
r
e
f
e
R

A
C
T
A
C
A
G
T
A
A
T
T
C
A
C
T
G
G
A
C
A
A
T
G
G

5
4
–
4
4

)
5
9
9
1
(

.
l
a

t
e

e
r
a
d
n
a
r
u
P

A
G
A
T
T
T
T
C
T
G
C
A
A
A
T
T
T
A
A
A
C
T
C
C
A
G

C
C
C
A
T
A
G
T
C
A
C
A
A
C
T
T
A
C
A
A
T
G
A
A

G
A
G
G
A
T
T
T
G
A
C
T
T
A
G
A
G
C
C
T
T
A
C

G
G
T
A
C
A
A
A
A
G
A
G
A
A
A
A
C
C
C
C
T

T
G
A
G
A
A
G
G
T
A
G
A
A
A
A
G
A
A
C
A
A
C
G
A

C
C
A
A
C
T
A
C
T
C
C
A
A
G
T
G
T
G
T
C
A
T
C

C
G
T
A
G
A
C
G
A
C
T
C
C
A
G
A
A
G
A
A
G
G
G
A
C
T

C
T
T
C
A
T
T
C
A
A
T
C
G
G
G
A
A
T
A
C
A
G
A
A
T
G

C
C
A
A
C
G
C
A
C
C
G
T
C
T
C
G
T
C
T
T
T
C
A
A
G
T

G
G
T
A
C
A
G
T
C
A
C
A
T
C
G
T
T
T
C
A
A
A
A
A
C

G
T
T
G
G
T
A
G
C
A
A
A
C
G
A
G
G
A
A
G
G
T
T
C

T
T
T
C
G
A
G
A
T
T
A
T
G
T
A
G
G
G
A
C
C
T
C
G

T
C
C
A
C
C
C
T
C
T
C
A
T
G
T
A
C
T
T
T
C
A
G
T

T
A
T
C
A
T
G
G
A
C
A
A
T
T
T
A
C
A
C
G
T
G

T
A
G
A
T
C
T
C
T
A
C
C
G
G
A
T
C
C
T
T
C

6
4

7
4

8
4

9
4

0
5

1
5

2
5

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
1
0
0
2
(

.
l
a

t
e

n
a
H

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
7
0
0
2
(

.
l
a

t
e

h
c
s
u
a
B

)
1
0
0
2
(

.
l
a

t
e

n
a
H

)
5
9
9
1
(

.
l
a

t
e

e
r
a
d
n
a
r
u
P

C
G
T
T
C
C
A
T
A
G
A
A
A
A
T
T
A
A
C
A
T
T
G
T
C

C
A
T
A
C
G
G
A
C
G
A
A
A
T
T
C
T
T
G
T
G
T
G
T

C
A
T
T
T
A
G
G
G
G
T
A
G
A
C
T
T
C
G
G
T
T
T
T

C
T
G
T
G
G
T
T
G
T
A
A
T
C
C
T
T
A
A
G
G
G
A
A

G
T
A
A
C
G
T
C
A
G
T
A
C
A
C
A
G
C
G
A
A

A
C
C
G
G
T
C
A
C
T
A
C
T
T
T
C
G
G
T

G
G
G
T
C
T
T
A
T
T
A
C
A
C
G
G
T
T
T
T
A
A

T
T
C
C
T
A
C
C
A
A
C
T
A
C
T
T
G
A
A
C
G
A

A
G
T
G
G
A
A
G
C
A
C
G
G
A
C
A
G
A
A
A

5
5

6
5

7
5

8
5

)
5
9
9
1
(

.
l
a

t
e

e
r
a
d
n
a
r
u
P

)
1
0
0
2
(

.
l
a

t
e

n
a
H

)
5
9
9
1
(

.
l
a

t
e

e
r
a
d
n
a
r
u
P

)
1
0
0
2
(

.
l
a

t
e

n
a
H

A
G
T
T
T
G
T
G
G
A
C
C
T
A
T
T
A
G
T
G
A
A
G
T

4
5
–
3
5

t
r
o
p
e
r

s
i
h
T

n
o
c
i
l
p
m
A

e
z
i
s

3
0
3

1
6
2

6
3
3

7
4
3

7
4
2

9
7
5

5
8
3

7
6
3

5
6
3

5
3
2

2
0
4

4
7
4

1
3
3

T
C
G
A
A
T
C
A
A
A
A
A
G
A
A
C
A
T
T
C
C
A
A
A

A
C
C
T
T
C
T
T
A
T
A
A
A
C
C
T
T
A
C
C
A
T
T
A

T
A
C
A
C
G
A
G
A
C
A
A
A
C
A
A
A
A
G
A
C

C
T
G
T
A
T
A
T
A
A
A
C
G
T
T
G
A
A
C
C
C

C
T
T
C
G
T
G
A
C
T
G
T
T
G
G
T
T
C
T
C

G
A
G
T
C
A
G
A
C
G
G
A
G
T
T
T
C
G
T
G

T
C
T
C
G
T
C
T
C
G
T
T
T
A
C
G
A
A
G
T

A
A
A
T
T
A
T
A
T
G
T
A
G
T
T
C
A
A
A
C
T
T
T
G

A
C
G
A
A
A
T
A
G
G
T
T
G
T
A
A
A
G
A
A
G
G

A
A
G
T
T
C
T
C
A
G
C
G
A
G
T
C
A
T
T
T
C
A

A
G
A
T
A
C
T
T
A
T
C
T
C
A
C
T
G
A
A
C
A
A
A

A
T
C
T
C
G
G
T
T
T
A
T
T
C
G
T
A
T
G
T
C
T
A
T

T
C
T
T
T
T
C
T
T
G
C
A
T
G
T
G
T
T
G
A
A
G
A

G
A
C
C
G
G
T
A
A
G
A
A
A
T
G
A
C
G
T
G

A
G
T
T
A
G
T
C
G
A
T
G
T
C
G
G
T
T
C
A

A
C
A
C
A
T
A
A
A
T
T
T
G
A
A
A
A
C
T
C
T
A

T
C
A
A
G
A
A
A
G
T
G
A
A
G
G
G
G
A
G
T

C
G
C
C
A
A
T
A
A
C
C
A
T
C
T
T
T
C
C
T
C

T
A
T
T
T
T
C
G
G
T
C
T
T
C
C
C
T
T
G
T
T

T
C
G
T
T
T
T
T
C
G
T
T
T
A
T
T
T
C
G
G

G
C
T
A
T
T
A
G
T
C
G
G
T
C
C
C
A
C
C

C
G
T
A
C
A
T
T
C
T
C
T
T
C
G
T
T
T
T
T
A
A
T

A
G
T
C
T
C
G
G
T
C
T
T
C
T
T
T
C
T
A
C

A
T
A
C
C
T
C
A
C
G
T
A
C
T
C
T
G
G
T

C
A
T
C
C
T
T
C
G
A
T
T
T
C
T
C
A
T
C
G
T

C
C
G
A
C
T
A
A
C
A
G
A
A
G
A
A
A
A
T
T
C
C

6
1

7
1

8
1

9
1

0
2

1
2

2
2

3
2

4
2

5
2

6
2

7
2

8
2

)
¢
3
-
¢
5
(

e
c
n
e
u
q
e
s

r
e
m
i
r
P

n
o
x
E

6

NEXT-GENERATION SEQUENCING IN NEUROFIBROMATOSIS TYPE 1

7

1995; Abernathy et al., 1997; Han et al., 2001; Bausch et al.,
2007). The 3¢ end of the primers were designed so as not to
match the genomic sequences of any of the highly homolo-
gous pseudogene sequences to avoid mispriming to the
pseudogenes. Direct capillary sequencing was performed
using the ABI BigDye version 1.1 Terminator Cycle Kit (Life
Technologies) and the ABI Prism 3500 Capillary Array Se-
quencer (Life Technologies). The sequence data were ana-
lyzed using Mutation Surveyor version 4.0.6 (Softgenetics)
and Sequencher version 5.0 (Gene Codes Corp.).

Multiplex ligation-dependent probe ampliﬁcation

When the next-generation sequencing protocol did not
identify truncating mutations, canonical splice-site muta-
tions, or other point mutations previously reported as path-
ological missense change or splicing defect, the remaining
samples were screened for single/multiple exon deletions or
duplications using a multiplex ligation-dependent probe
ampliﬁcation method (De Luca et al., 2007) (SALSA P081/
082-B2 NF1 MLPA assay kit; MRC-Holland) concurrently
with the direct capillary sequencing of all the exons, as
stated above.

Analysis algorithm of the variants

Missense variants that have not been reported as patho-
genic in the literature and were not observed in the 1208
normal Japanese exome data were evaluated for potential
pathogenicity using ﬁve bioinformatics programs, including
SIFT (Kumar et al., 2009), Polyphen2 (Adzhubei et al.,
2010), LRT (Chun and Fay, 2009), MutationTaster (Schwarz
et al., 2010), and PhyloP (Siepel et al., 2009). When four of
the ﬁve programs predicted the results as pathogenic
(‘‘damaging’’ with SIFT, ‘‘probably damaging’’ with Poly-
Phen2, ‘‘deleterious’’ with LRT, ‘‘disease causing’’ with
MutationTaster, or ‘‘conserved’’ with PhyloP), we inter-
preted the clinical signiﬁcance of the missense mutation as
being putatively pathogenic.

Results

Performance of sequence capturing

In the custom-designed mutation analysis panel for the
screening of classic genetic syndromes, the number of bases
for targeted capturing was 459,952 bp over 1888 regions of
the 109 target genes, including NF1. An average of 207,203
reads per sample were mapped and aligned uniquely to the
targeted bases of the 109 genes among the 86 samples.

As far as the NF1 locus was concerned, all the exons were
highly covered with a coverage of 190.7x per sample.
Overall, 99.3% of the regions were covered at least with a
coverage of 5x and 98.8% of the regions were covered at least
with a coverage of 30x. The mean coverage of all the exons in
the 86 samples indicated that all the exons, but exon 1, were
appropriate for base calling by next-generation sequencing
(Table 3). Because of the poor coverage, exon 1 was se-
quenced using the direct capillary sequencing in all 86
samples, none of which had any variants.

The mean coverage over the entire targeted regions per
sample was 131.0x, and most of the regions were well cov-
ered (Table 4). Overall, 97.1% of the regions were covered at
least 5x coverage, and 84.4% of the regions were covered at

Table 3. Mean Coverage of NF1 Exons

Among 86 Patients

Exon

Coverage (x)

Exon

Coverage (x)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

1.7
220.2
168.8
169.5
145.0
170.9
164.8
144.0
182.7
174.1
179.2
194.9
120.0
141.2
86.9
152.7
212.6
251.3
127.1
215.4
175.2
191.4
103.1
194.0
96.6
212.1
209.6
238.7
208.5

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

239.7
175.9
157.0
124.6
216.0
152.1
189.3
284.7
261.5
230.9
217.3
206.8
276.9
195.7
181.1
166.3
156.4
185.7
159.4
241.5
79.1
174.3
238.4
235.9
217.5
136.8
320.0
220.5
122.6

least 30x coverage. Some exons of NF1 and other regions
were less well covered than others. Exon 15 and exon 50 of
NF1, together with the COMP gene and the PHOX2B gene,
had relatively low coverages of 86.9x, 79.1x, 55.3x, and
19.2x, respectively.

NF1 has seven highly homologous pseudogene sequences
located in chromosomes other than chromosome 17 (2q12-
q13, 12q11, 14p11-q11, 15q11.2, 18p11.2, 21p11-q11, and
22p11-q11), on which NF1 resides (Upaddhyaya, 2008). We
scrutinized the mapped reads among 10 arbitrarily selected
patients; all the pseudogene sequences were mapped to their
orthologous locations in the genome rather than the NF1
locus on chromosome 17.

Coverage of the 108 genes other than the NF1 gene was
evaluated in all 86 samples. The mean coverage of all 108
genes on the same diagnostic panel indicated that the mean
coverage ranged from 19.2x to 254.1x, with mean of 114.5x
(Table 4).

Mutation detection

The next-generation sequencing protocol described above
led to the identiﬁcation of pathological NF1 mutations in 70
of the 86 patients who met the NIH diagnostic criteria. The
clinical information is listed in Table 5. All the 70 patients
harbored mutations in a heterozygous state: 30 nonsense
mutations, 19 frameshift mutations, 8 canonical splice-site
mutations, and 6 point mutations that were previously re-
ported and have been shown to lead to aberrant splicing

8

MARUOKA ET AL.

Table 4. Summary of the Coverage of 109 Genes

Gene

Coverage (x)

Gene

Coverage (x)

ACTA2
ACTC1
ACVRL1
BRAF
CBL
CDKL5
CHD7
COL11A1
COL11A2
COL1A1
COL1A2
COL2A1
COL3A1
COL5A1
COL5A2
COL9A1
COL9A2
COMP
CREBBP
CUL7
DCC
DDX3X
ECE1
EDN3
EDNRB
EFNB1
ENG
EP300
FBN1
FBN2
FGFR1
FGFR2
FGFR3
GDNF
GFRA1
GFRA2
GLA
HRAS
IHH
IRF6
JAG1
KCNE1
KCNJ2
KCNQ1
KIAA1279
KIF26A
KRAS
L1CAM
LAMP2
MAP2K1
MAP2K2
MAPK1
MAPK3
MECP2
MID1

103.7
111.4
60.4
160.0
192.3
146.1
150.6
160.5
66.8
47.2
127.0
76.2
123.1
52.0
159.2
147.4
52.4
55.3
50.1
68.8
188.4
118.1
80.6
64.6
178.9
47.8
36.4
191.0
177.2
171.0
102.7
157.5
34.8
200.5
103.1
49.9
121.1
44.4
73.4
128.5
147.5
88.4
226.4
80.5
186.5
33.7
214.4
42.7
128.2
151.4
35.6
168.5
87.1
80.4
126.4

MSX1
MYH7
MYH9
NF1
NIPBL
NOTCH2
NRAS
NRTN
NSD1
OTX2
PHOX2B
PKHD1
PLOD1
PSPN
PTCH1
PTPN11
RAD21
RAF1
RASA1
RET
RUNX2
SALL1
SALL4
SCN1B
SHH
SHOC2
SIX3
SIX6
SMC1A
SMC3
SOS1
SOX10
SOX2-OT
SPRED1
SPRY2
STAG1
TAZ
TBX22
TBX5
TCF4
TCOF1
TGFBR1
TGFBR2
TGIF1
TP63
TRAPPC10
TRIM37
TSC1
TSC2
TWIST1
VHL
VSX2
ZEB2
ZIC2

49.4
103.5
97.5
190.7
175.9
153.4
254.1
45.8
160.1
115.1
19.2
173.6
68.3
66.5
111.0
152.6
198.5
154.9
171.7
97.4
144.5
91.7
93.8
69.3
50.3
195.5
80.0
67.6
134.7
157.2
180.5
45.1
89.0
137.0
141.7
193.3
45.1
117.7
124.2
170.8
68.4
190.0
89.6
77.1
182.5
139.7
85.4
157.8
49.4
47.9
84.5
29.7
218.9
72.9

according to reverse transcription (RT)-PCR studies, together
with seven nonsynonymous substitutions (Table 5). Among
the seven nonsynonymous substitutions, four were previ-
ously reported to be pathogenic based on functional assays or
the inheritance pattern within the families (Li et al., 1992;
Fahsold et al., 2000; Lee et al., 2006).

Three samples with missense mutations that have never
been reported in the literature were predicted to be patho-
genic based on the consensus predication from multiple
bioinformatics programs. Five programs, including SIFT,
Polyphen2, LRT, Mutation Taster, and PhyloP, predicted
potential pathogenicity as follows: c.2183T > G (p.Val728Gly)
mutation was predicted to be pathogenic by all ﬁve pro-
grams, and c.2540T > G (p.Leu847Arg) and c.6818A > T
(p.Lys2273Met) mutations were predicted to be pathogenic
by four of the ﬁve bioinformatics programs. None of the
three missense mutations resided within the critical functional
domain, GAP-related domain that regulates the RasGAP
activity.

Comparison of the distributions of nonsense, splice-site
variants, and missense mutations in the Japanese population
versus the northern European population, as reported by
Messiaen et al. (2000), Nemethova et al. (2013), Sabbagh
et al. (2013), and Valero et al. (2011), revealed no statisti-
cally signiﬁcant differences among the groups ( p = 0.203
using the Fisher exact test for countable data).

Together with these 3 samples, which were subject to
bioinformatics programs, 16 samples without
truncating
mutations or missense mutations, previously reported to be
pathogenic, were further sequenced using direct capillary
sequencing methods. All the exons were sequenced, includ-
ing exon 1, and no additional point mutations or small indels
were detected. These 19 patients were further screened for
relatively large deletions that would span an entire exon or
multiple exons and thus escape from direct capillary se-
quencing. Among 10 patients, 5 were shown to have a whole
NF1 deletion, 2 had multiple-exon deletions, and 3 had
single-exon deletions. These ﬁve patients with a whole NF1
deletion were apparently homozygous for all the SNPs for
the entire NF1 region according to the next-generation se-
quencing analysis.

Overall, no appreciable genotype–phenotype correlation
was detected in the present study (Table 5). Variants were
detected in genes other than NF1 when the same criteria used
in the NF1 analysis were applied to these genes (Table 5).
None of these variants was classiﬁed as truncating mutations
and none of them listed in the Human Genome Mutation
Database (HGMD) (Cooper et al., 1998). Such rare variants
of unknown signiﬁcance among the genes on the panel were
found in at least two-thirds of the patients. Patients with
variants in genes other than NF1 did not necessarily exhibit a
severe NF1 phenotype.

Discussion

The present study demonstrated that next-generation se-
quencing with in-solution hybridization-based enrichment
provides a high mutation detection rate comparable to that of
conventional direct capillary sequencing methods for the
molecular diagnosis of neuroﬁbromatosis. The overall mu-
tation detection rate using the currently reported method in 86
patients who met the clinical diagnostic criteria was 81.4%
(70/86). Among the 16 samples in which mutations were not
detected using next-generation sequencing, 10 samples were
later shown to have large deletions using a different method,
multiplex ligation-dependent probe ampliﬁcation (MLPA).
Because of their large sizes, the 10 large deletions would not
have been detected using the direct capillary sequencing

g
n
i
c
n
e
u
q
e
S

n
o
i
t
a
r
e
n
e
G
-
t
x
e
N
y
b

d
e
t
c
e
t
e
D
s
n
o
i
t
a
t
u
M
c
i
n
e
g
o
h
t
a
P

f
o

y
r
a
m
m
u
S

.

5

e
l
b
a
T

f
o

r
e
b
m
u
N

n
i

s
n
o
i
t
a
t
u
m

s
e
n
e
g

r
e
h
t
o

n
w
o
n
k
n
u

f
o

s
n
o
i
t
a
i
r
a
V

n
i

e
c
n
a
c
ﬁ
i
n
g
i
s

s
e
n
e
g

y
h
t
a
p
o
s
a
r

s
m
o
t
p
m
y
S

l
a
i
l
i

m
a
F

e
g
A

e
c
n
e
r
e
f
e
R

f
o

e
p
y
T

n
o
i
t
a
t
u
m

d
i
c
a

o
n
i
m
A

n
o
i
t
u
t
i
t
s
b
u
s

n
o
i
t
a
t
u
m
c
i
m
o
n
e
G

n
o
x
E

2

1

1

1

1

2

1

1

1

1

1

0

1

0

1

2

1

0

0

0

1

3

2

2

1

1

0

0

1

0

0

)
d
e
u
n
i
t
n
o
c
(

T
>
C
3
9
2

.
c

1
A
S
A
R

l
a
V
8
9
a
l
A
p

.

N
P

,

,

N
B
P

,

,

N
O
B
P

,

,

,

L
N
P

,

,

L
N
B
P

,

,

C
>
G
9
6
6

.
c

1
A
S
A
R

s
i
H
3
2
2
n
l
G
p

.

,

L
N
P

,

,

L
N
P

,

,

L
N
P

,

,

N
B
P

,

P

,

N
B
P

,

,

N
B
P

,

N
P

,

,

N
B
P

,

,

L
N
P

,

,

L
N
P

,

,

N
B
P

,

,

N
B
P

,

N
P

,

N
P

,

N
P

,

,

L
N
P

,

,

L
N
B
P

,

,

N
P

,

N
P

,

,

N
B
P

,

,

L
N
B
P

,

,

,

L
N
P

,

N
P

,

N
P

,

,

L
N
B
P

,

,

s
e
Y

s
e
Y

s
e
Y

o
N

o
N

o
N

s
e
Y

o
N

s
e
Y

o
N

s
e
Y

s
e
Y

o
N

s
e
Y

o
N

o
N

o
N

s
e
Y

o
N

s
e
Y

o
N

o
N

s
e
Y

s
e
Y

o
N

s
e
Y

s
e
Y

s
e
Y

s
e
Y

s
e
Y

s
e
Y

8
6

4
4

0
5

1
4

7
2

2
3

0
4

1
2

3

2
3

7
6

1
4

6
3

3
6

1
7

0
3

2
5

0
4

6
3

9
4

0
4

0
8

9
7

7
5

3
2

5
3

8
5

7
6

3
4

3
3

9
5

)
6
0
0
2
(

.
l
a

t
e

e
e
L

.
l
a

t
e

n
e
a
i
s
s
e
M

.
l
a

t
e

n
e
a
i
s
s
e
M

.
l
a

t
e

n
e
a
i
s
s
e
M

)
0
0
0
2
(

)
0
0
0
2
(

)
0
0
0
2
(

)
4
9
9
1
(

.
l
a

t
e

e
r
a
d
n
a
r
u
P

)
6
9
9
1
(

.
l
a

t
e

i
n
i
r
a
p
s
a
G

.
l
a

t
e

d
l
o
s
h
a
F

.
l
a

t
e

d
l
o
s
h
a
F

)
0
0
0
2
(

)
0
0
0
2
(

t
f
i
h
s
e
m
a
r
F

9
*
s
f
u
l
G
9
2
n
s
A
p

.

G
s
n
i
4
8
_
3
8
.
c

t
f
i
h
s
e
m
a
r
F

t
f
i
h
s
e
m
a
r
F

t
f
i
h
s
e
m
a
r
F

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

a
e
s
n
e
s
s
i

M

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

a
e
s
n
e
s
s
i

M

a
e
s
n
e
s
s
i

M

a
e
s
n
e
s
s
i

M

t
f
i
h
s
e
m
a
r
F

g
n
i
c
i
l
p
S

g
n
i
c
i
l
p
S

t
f
i
h
s
e
m
a
r
F

e
s
n
e
s
n
o
N

t
f
i
h
s
e
m
a
r
F

e
s
n
e
s
n
o
N

t
f
i
h
s
e
m
a
r
F

a
e
s
n
e
s
s
i

M

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
s
i

M

t
f
i
h
s
e
m
a
r
F

a
e
s
n
e
s
s
i

M

8
1
*
s
f
n
s
A
9
8
r
h
T
p

.

*
4
6
1
u
e
L
p

.

0
1
*
s
f
n
l
G
7
6
1
s
y
C
p

.

7
*
s
f
p
r
T
7
6
1
s
y
C
p

.

g
r
A
4
1
4
u
e
L
p

.

*
2
9
1
g
r
A
p

.

*
9
6
3
n
l
G
p

.

*
6
1
4
g
r
A
p

.

*
1
6
4
g
r
A
p

.

s
y
C
9
8
4
r
y
T
p

.

*
1
6
4
g
r
A
p

.

*
1
6
4
g
r
A
p

.

s
y
C
9
8
4
r
y
T
p

.

s
y
C
9
8
4
r
y
T
p

.

3
4
*
s
f
g
r
A
4
1
5
n
l
G
p

.

8
1
*
s
f
l
a
V
6
8
5
r
h
T
p

.

7
1
*
s
f
e
l
I
4
1
6
n
s
A
p

.

6
*
s
f
u
e
L
8
2
6
r
y
T
p

.

g
r
A
9
2
6
y
l
G
p

.

*
9
8
5
n
l
G
p

.

*
6
7
5
n
l
G
p

.

2
1
*
s
f
r
h
T
9
0
8
s
i
H
p

.

o
r
P
7
4
8
u
e
L
p

.

y
l
G
8
2
7
l
a
V
p

.

*
1
8
6
g
r
A
p

.

*
1
8
6
g
r
A
p

.

*
6
9
6
p
r
T
p

.

a
e
s
n
e
s
s
i

M

o
r
P
7
4
8
u
e
L
p

.

T
T
G
T
l
e
d
8
9
4
-
5
9
4
.
c

A
s
n
i
5
6
2
_
4
6
2
.
c

A
>
T
1
9
4
.
c

G
s
n
i
0
0
5
_
9
9
4
.
c

T
>
C
5
0
1
1
.
c

G
>
T
1
4
2
1
.
c

T
>
C
4
7
5
.
c

A
A
T
G
l
e
d
4
+
_
1
+
7
2
5
1
.
c

G
A
l
e
d
2
4
5
1
_
1
4
5
1
.
c

G
>
A
3
+
1
2
7
1
.
c

A
T
C
A
l
e
d
7
5
7
1
_
4
5
7
1
.
c

T
<
C
5
6
7
1
.
c

T
>
C
6
2
7
1
.
c

T
s
n
i
7
7
8
1
_
6
7
8
1
.
c

A
>
G
5
8
8
1
.
c

T
l
e
d
2
3
8
1
.
c

G
>
A
6
6
4
1
.
c

G
>
A
6
6
4
1
.
c

T
>
C
6
4
2
1
.
c

T
>
C
1
8
3
1
.
c

T
>
C
1
8
3
1
.
c

T
>
C
1
8
3
1
.
c

G
>
A
6
6
4
1
.
c

T
>
C
1
4
0
2
.
c

T
>
C
1
4
0
2
.
c

A
>
G
7
8
0
2
.
c

G
>
T
3
8
1
2
.
c

C
>
T
0
4
5
2
.
c

T
l
e
d
3
2
4
2
.
c

C
>
T
0
4
5
2
.
c

2

3

5

5

5

5

0
1

1
1

1
1

2
1

2
1

2
1

3
1

3
1

3
1

3
1

4
1

5
1

6
1

6
1

6
1

6
1

7
1

7
1

8
1

8
1

b
8
1

8
1

1
2

1
2

1
2

9

f
o

r
e
b
m
u
N

n
i

s
n
o
i
t
a
t
u
m

s
e
n
e
g

r
e
h
t
o

n
w
o
n
k
n
u

f
o

s
n
o
i
t
a
i
r
a
V

n
i

e
c
n
a
c
ﬁ
i
n
g
i
s

s
e
n
e
g

y
h
t
a
p
o
s
a
r

s
m
o
t
p
m
y
S

l
a
i
l
i

m
a
F

e
g
A

e
c
n
e
r
e
f
e
R

f
o

e
p
y
T

n
o
i
t
a
t
u
m

d
i
c
a

o
n
i
m
A

n
o
i
t
u
t
i
t
s
b
u
s

n
o
i
t
a
t
u
m
c
i
m
o
n
e
G

)
d
e
u
n
i
t
n
o
C

(

.

5

e
l
b
a
T

0

0

1

0

0

2

1

2

1

0

2

0

0

1

0

0

2

2

1

2

1

1

1

1

0

1

0

1

3

0

1

1

)
d
e
u
n
i
t
n
o
c
(

,

L
N
B
P

,

,

,

L
N
P

,

N
P

,

,

N
B
P

,

,

N
O
P

,

,

L
N
P

,

,

L
N
P

,

,

N
B
P

,

,

L
N
B
P

,

,

,

L
N
B
P

,

,

,

L
N
B
P

,

,

,

,

L
N
B
O
P

,

,

,

L
N
B
P

,

,

,

L
N
P

,

N
P

,

,

L
N
P

,

,

N
B
P

,

N
P

,

,

L
N
B
P

,

,

,

L
N
B
P

,

,

,

N
B
P

,

N
P

,

,

L
N
B
P

,

,

,

L
N
P

,

,

L
N
B
P

,

,

,

N
B
P

,

,

N
B
P

,

N
P

,

,

N
B
O
P

,

,

N
P

,

,

L
N
B
P

,

,

N
P

,

o
N

s
e
Y

o
N

s
e
Y

s
e
Y

o
N

o
N

s
e
Y

s
e
Y

o
N

o
N

o
N

o
N

o
N

s
e
Y

o
N

s
e
Y

s
e
Y

o
N

o
N

o
N

o
N

o
N

o
N

s
e
Y

s
e
Y

s
e
Y

o
N

o
N

s
e
Y

s
e
Y

o
N

5
5

2
5

9
1

0
5

2
1

9
2

0
2

7
3

4
6

4
4

9
2

1
2

9
4

7
2

0
5

0
4

9
4

5
3

0
5

6
3

5
4

3
6

0
4

8
3

9
3

1
3

9
6

2
2

4
5

9
6

2
5

6
4

)
2
9
9
1
(

.
l
a

t
e

i

L

)
3
0
0
2
(

.
l
a

t
e

s
r
A

e
s
n
e
s
s
i

M

e
s
n
e
s
n
o
N

g
n
i
c
i
l
p
S

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

t
f
i
h
s
e
m
a
r
F

t
f
i
h
s
e
m
a
r
F

t
f
i
h
s
e
m
a
r
F

t
f
i
h
s
e
m
a
r
F

g
n
i
c
i
l
p
S

7
1
*
s
f
g
r
A
9
9
1
1
r
h
T
p

.

2
1
*
s
f
u
e
L
5
0
2
1
e
h
P
p

.

2
1
*
s
f
u
e
L
5
0
2
1
e
h
P
p

.

6
1
*
s
f
s
i
H
2
7
0
1
r
e
S
p

.

*
6
1
0
1
s
y
C
p

.

*
4
4
0
1
r
y
T
p

.

g
r
A
7
4
8
u
e
L
p

.

*
6
1
8
g
r
A
p

.

t
f
i
h
s
e
m
a
r
F

0
1
*
s
f
s
y
C
7
5
2
1
u
e
L
p

.

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

t
f
i
h
s
e
m
a
r
F

a
e
s
n
e
s
s
i

M

5
2
*
s
f
g
r
A
4
4
4
1
s
y
L
p

.

u
l
G
0
4
4
1
s
y
L
p

.

*
6
7
2
1
g
r
A
p

.

*
6
9
2
1
r
y
T
p

.

*
2
6
3
1
g
r
A
p

.

g
n
i
c
i
l
p
S

g
n
i
c
i
l
p
S

t
f
i
h
s
e
m
a
r
F

9
5
*
s
f
g
r
A
5
1
5
1
n
l
G
p

.

t
f
i
h
s
e
m
a
r
F

9
3
*
s
f
g
r
A
2
8
5
1
u
l
G
p

.

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

g
n
i
c
i
l
p
S

g
n
i
c
i
l
p
S

t
f
i
h
s
e
m
a
r
F

a
e
s
n
e
s
s
i

M

1
2
*
s
f
o
r
P
1
4
8
1
u
l
G
p

.

n
l
G
0
7
8
1
g
r
A
p

.

*
0
9
5
1
u
e
L
p

.

*
5
2
6
1
r
y
T
p

.

*
3
3
7
1
u
e
L
p

.

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
s
i

M

*
8
6
9
1
g
r
A
p

.

*
5
2
2
2
p
r
T
p

.

*
8
5
2
2
g
r
A
p

.

*
8
5
2
2
g
r
A
p

.

t
e
M
3
7
2
2
s
y
L
p

.

A
T
T
T
l
e
d
2
-
_
5
-
1
5
8
2
.
c

A
>
T
8
4
0
3
.
c

A
>
C
2
3
1
3
.
c

A
A
l
e
d
4
1
2
3
_
3
1
2
3
.
c

G
G
s
n
i
6
9
5
3
_
5
9
5
3
.
c

G
T
l
e
d
6
1
6
3
_
5
1
6
3
.
c

G
T
l
e
d
6
1
6
3
_
5
1
6
3
.
c

G
>
A
2
-
9
0
7
3
.
c

G
>
T
0
4
5
2
.
c

T
>
C
6
4
4
2
.
c

T
C
s
n
i
6
6
7
3
_
5
6
7
3
.
c

T
>
C
6
2
8
3
.
c

A
>
T
8
8
8
3
.
c

T
>
C
4
8
0
4
.
c

A
>
G
1
+
0
3
4
4
.
c

G
>
A
0
3
3
4
.
c

A
l
e
d
9
2
3
4
.
c

G
A
A
A
T
G
G
A
T
C
A
G
T
A
T
l
e
d

6
+
4
2
7
4
_
6
1
7
4
.
c

A
l
e
d
4
4
5
4
.
c

C
T
T
G
G
T
T
G
G
A
C
C
T
T
l
e
d

A
>
G
1
-
9
6
2
5
.
c

C
s
n
i
7
1
5
5
_
6
1
5
5
.
c

A
>
G
9
0
6
5
.
c

G
A
l
e
d
4
4
7
4
_
3
4
7
4
.
c

G
>
T
9
6
7
4
.
c

A
s
n
i
4
7
8
4
_
3
7
8
4
.
c

G
>
T
8
9
1
5
.
c

6
7
2
5
_
6
-
9
6
2
5
.
c

T
>
C
2
0
9
5
.
c

A
>
G
5
7
6
6
.
c

T
>
C
2
7
7
6
.
c

T
>
C
2
7
7
6
.
c

T
>
A
8
1
8
6
.
c

n
o
x
E

b
1
2

1
2

2
2

3
2

4
2

5
2

7
2

7
2

7
2

8
2

8
2

8
2

9
2

0
3

2
3

2
3

3
3

4
3

5
3

6
3

6
3

7
3

7
3

8
3

8
3

8
3

8
3

0
4

4
4

5
4

b
5
4

5
4

10

1

0

0

1

0

0

2

3

1

1

1

1

1

0

2

0

1

0

0

2

0

1

0

N
P

,

N
P

,

N
P

,

,

L
N
P

,

,

L
N
B
P

,

,

,

L
N
B
P

,

,

,

L
N
P

,

,

L
N
P

,

N
P

,

N
P

,

,

L
N
B
P

,

,

,

N
B
P

,

,

L
N
P

,

,

L
N
P

,

,

L
N
P

,

N
P

,

N
P

,

N
P

,

P

,

L
N
P

,

N
P

,

,

N
B
P

,

P

s
e
Y

o
N

o
N

s
e
Y

o
N

o
N

s
e
Y

o
N

o
N

o
N

o
N

o
N

o
N

o
N

s
e
Y

s
e
Y

o
N

o
N

o
N

s
e
Y

o
N

s
e
Y

o
N

2
4

1
2

8
2

7
3

5
2

6
4

1
4

3
1

9
2

8
6

8
5

4
3

8
6

9
5

6
3

8
2

5
5

7
3

0
5

5
4

0
3

4
3

5
2

f
o

r
e
b
m
u
N

n
i

s
n
o
i
t
a
t
u
m

s
e
n
e
g

r
e
h
t
o

n
w
o
n
k
n
u

f
o

s
n
o
i
t
a
i
r
a
V

n
i

e
c
n
a
c
ﬁ
i
n
g
i
s

s
e
n
e
g

y
h
t
a
p
o
s
a
r

s
m
o
t
p
m
y
S

l
a
i
l
i

m
a
F

e
g
A

e
c
n
e
r
e
f
e
R

n
o
i
t
e
l
e
d

n
o
i
t
e
l
e
d

n
o
i
t
e
l
e
d

n
o
i
t
e
l
e
d

n
o
i
t
e
l
e
d

8
5

8
5

8
5

8
5

8
5

o
t

o
t

o
t

o
t

o
t

n
o
i
t
e
l
e
d

1
5

n
o
i
t
e
l
e
d

4

o
t

o
t

n
o
i
t
e
l
e
d

n
o
i
t
e
l
e
d

1
x
e

1
x
e

1
x
e

1
x
e

1
x
e

1
x
e

3
x
e

6
x
e

8
x
e

n
o
i
t
e
l
e
d

2
1
x
e

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

e
s
n
e
s
n
o
N

g
n
i
c
i
l
p
S

*
5
8
2
2
r
y
T
p

.

*
5
8
2
2
r
y
T
p

.

*
2
0
3
2
n
l
G
p

.

*
7
1
3
2
p
r
T
p

.

*
0
5
4
2
g
r
A
p

.

f
o

e
p
y
T

n
o
i
t
a
t
u
m

d
i
c
a

o
n
i
m
A

n
o
i
t
u
t
i
t
s
b
u
s

t
f
i
h
s
e
m
a
r
F

5
*
s
f
r
h
T
5
8
2
2
r
y
T
p

.

)
d
e
u
n
i
t
n
o
C

(

.

5

e
l
b
a
T

n
o
i
t
a
t
u
m
c
i
m
o
n
e
G

n
o
x
E

T
T
C
A
l
e
d
3
5
8
6
_
0
5
8
6
.
c

A
s
n
i
4
5
8
6
_
3
5
8
6
.
c

A
s
n
i
4
5
8
6
_
3
5
8
6
.
c

T
>
C
4
0
9
6
.
c

A
>
G
0
5
9
6
.
c

T
>
C
8
4
3
7
.
c

A
A
T
G
l
e
d
4
+
_
1
+
0
7
9
7
.
c

6
4

6
4

6
4

6
4

7
4

0
5

4
5

11

.
e
s
a
b
a
t
a
D
n
o
i
t
a
t
u
M
e
m
o
n
e
G
n
a
m
u
H

;

D
M
G
H

;
s
e
l
u
d
o
n

h
c
s
i
L

,

L

;
a
m
o
r
b
ﬁ
o
r
u
e
n

,

N

;
n
o
i
t
a
t
s
e
f
i
n
a
m
e
n
o
b

,

B

;
r
o
m
u
t

e
v
r
e
n

c
i
t
p
o

,

O

;
t
n
e
m
g
i
p

,

P

:
s

m
o
t
p
m
y
S

.
s

m
a
r
g
o
r
p

s
c
i
t
a
m
r
o
f
n
i
o
i
b

y
b

c
i
n
e
g
o
h
t
a
p

e
b

o
t

.

g
n
i
c
i
l
p
s

t
n
a
r
r
e
b
a

e
s
u
a
c

o
t

d
e
t
r
o
p
e
r

y
l
s
u
o
i
v
e
r
P
a

d
e
t
c
i
d
e
r
P
b

12

MARUOKA ET AL.

method, which is currently considered to be the gold stan-
dard. The mutation detection rate was 92.1% (70/76) when
these 10 samples were excluded from the calculation of the
detection rate.

Among the 10 samples with large deletions, 5 patients with
a whole NF1 deletion could have been suspected of having a
whole gene deletion, in that these patients were apparently
homozygous for all the SNPs for the entire NF1 region ac-
cording to the next-generation sequencing data. The re-
maining ﬁve patients with a partial deletion of the NF1 gene,
as documented using MLPA, would not have been reliably
inferred to have such a deletion based on the relatively short
runs of homozygosity.

Recent reports on comprehensive NF1 screening using the
direct capillary sequencing method revealed that the detec-
tion rate was 89.5–96.3% when cases with large deletions
detectable only by using MLPA were excluded [93.4%:
Valero et al. (2011), 89.5%: Nemethova et al. (2013), 96.3%:
Sabbagh et al. (2013)]. Hence, the performance of the pres-
ently reported protocol was comparable with that of the direct
capillary sequencing methods.

The present protocol uses genomic DNA as the starting
material, unlike other protocols using puromycin-tested
Epstein-Barr virus cell lines as the starting material for RT-
PCR (Messiaen et al., 2000). Apparently, the use of genomic
DNA is much easier in clinical settings. Yet, genetic testing
based on genomic DNA, including the previously reported
protocol, cannot predict potential splicing defects caused by
point mutations. The use of RNA would be more sensitive to
splicing abnormalities, if any, because of the possibility of
mutations located deep in the intron or aberrant splicing de-
fects caused by point mutations within coding sequences that
were not evaluated in the presently reported protocol. How-
ever, such deep intronic mutations or splicing defects may be
relatively rare, given the high overall detection rate of 92.1%
in the present study.

The mean coverage of the entire target regions per sample
was 131.0x. This coverage ﬁgure was considered to be sufﬁ-
cient for the detection of heterozygous base changes. Fur-
thermore, the observation that rare variants in some genes on
the panel were found in at least two-thirds of the patients
supports the notion that the diagnostic performance of the
panel for other genes is as robust as it is for NF1. Thus, our
results regarding the validity of next-generation sequencing for
the molecular diagnosis of the NF1 gene, in comparison with
direct capillary sequencing, can be extrapolated to the mo-
lecular diagnosis of other classic malformation syndromes.

Nevertheless, exon-to-exon variations in the coverage ﬁg-
ures should be carefully evaluated. The extremely low cov-
erage of the NF1 exon1 can be ascribed to its extremely high
GC content of 77.5%, in that a GC content of 60% or higher is
associated with a sharp decrease in the read depth (Chilama-
kuri et al., 2014). Similarly, a relatively low coverage of the
COMP gene of 55.3x may be associated with a GC content of
63.4%. Exon 15 and exon 50 of NF1, together with the
PHOX2B gene, had relatively low coverages of 86.9x, 79.1x,
and 19.2x, respectively. The underlying cause of such varia-
tions is currently unexplained in that the GC contents of these
regions were 32.2%, 39.4%, and 54.5%, respectively.

We estimated that the cost for consumables would be about
USD 400 for direct capillary sequencing of the NF1 gene,
excluding labor costs. The estimated cost for consumables for

the NGS panel analysis would be comparable. Hence, if we
were to screen for the single NF1 gene, the cost–beneﬁt of
next-generation sequencing may not be advantageous. How-
ever, if we were to screen for genes associated with conditions
to be differentiated from neuroﬁbromatosis using direct cap-
illary sequencing, the consumable cost would be multiplied,
whereas the cost for the screening of extra genes using next-
generation sequencing would remain ﬁxed. Indeed, the mo-
lecular diagnosis of Legius syndrome and Noonan syndrome
would be helpful for the clinical management and outcome
predictions of patients with cafe´-au-lait spots, since patients
with these conditions are unlikely to develop neuroﬁbromas
or other hamartomatous complications.

The availability of a mutation analysis panel, like the one
presented herein, plays a critical role in differentiating the
underlying genetic cause of patients whose diagnosis is un-
certain from a clinical standpoint (Takenouchi et al., 2013a,
2013b). The use of a whole-exome panel would be advan-
tageous because of its comprehensiveness. However, apart
from the higher cost of a whole-exome analysis, a panel ap-
proach enables a higher sensitivity (Chin et al., 2013) be-
cause the average coverage, and thus the sensitivity, is higher
using a panel approach (close to 100%) compared with a
whole-exome approach (85%–95%).

Acknowledgments

All the authors would like to express their sincere appreci-
ation to Mr. Yuji Sugie for his special support and all the
patients and their families who were enrolled in this study. This
work was partly supported by Research on Applying Health
Technology and Research on Rare and Intractable Diseases
from the Ministry of Health, Labour and Welfare, Japan.

Author Disclosure Statement

The authors declare that they have no competing interests.

References

Abernathy CR, Rasmussen SA, Stalker HJ, et al. (1997) NF1
mutation analysis using a combined heteroduplex/SSCP ap-
proach. Hum Mutat 9:548–554.

Adzhubei IA, Schmidt S, Peshkin L, et al. (2010) A method and
server for predicting damaging missense mutations. Nat
Methods 7:248–249.

Aoki Y, Niihori T, Narumi Y, et al. (2008) The RAS/MAPK
syndromes: novel roles of the RAS pathway in human genetic
disorders. Hum Mutat 29:992–1006.

Aramaki M, Udaka T, Torii C, et al. (2006) Screening for
CHARGE syndrome mutations in the CHD7 gene using de-
naturing high-performance liquid chromatography. Genet
Test Mol Biomarkers 10:244–251.

Ars E, Kruyer H, Morell M, et al. (2003) Recurrent mutations in
the NF1 gene are common among neuroﬁbromatosis type 1
patients. J Med Genet 40:e82.

Bausch B, Borozdin W, Mautner VF, et al. (2007) Germline
NF1 mutational spectra and loss-of-heterozygosity analyses
in patients with pheochromocytoma and neuroﬁbromatosis
type 1. J Clin Endocrinol Metab 92:2784–2792.

Carey JC, Viskochil DH (1999) Neuroﬁbromatosis type 1:
A model condition for the study of the molecular basis of
variable expressivity in human disorders. Am J Med Genet
89:7–13.

NEXT-GENERATION SEQUENCING IN NEUROFIBROMATOSIS TYPE 1

13

Chilamakuri CS, Lorenz S, Madoui MA, et al. (2014) Perfor-
mance comparison of four exome capture systems for deep
sequencing. BMC Genomics 15:449.

Chin E, Zhang V, Wang J, et al. (2013) Frequently asked
questions about
the clinical utility of next-generation se-
quencing in molecular diagnosis of human genetic diseases.
In: Wong L-JC (ed) Next Generation Sequencing: Translation
to Clinical Diagnostics. Springer Science + Business Media,
New York, pp 287–299.

Chun S, Fay JC (2009) Identiﬁcation of deleterious mutations

within three human genomes. Genome Res 19:1553–1561.

Cingolani P, Platts A, Wang le L, et al. (2012) A program for
annotating and predicting the effects of single nucleotide
polymorphisms, SnpEff: SNPs in the genome of Drosophila
melanogaster strain w1118; iso-2; iso-3. Fly 6:80–92.

Cooper DN, Ball EV, Krawczak M (1998) The human gene

mutation database. Nucleic Acids Res 26:285–287.

De Luca A, Bottillo I, Dasdia MC, et al. (2007) Deletions of
NF1 gene and exons detected by multiplex ligation-dependent
probe ampliﬁcation. J Med Genet 44:800–808.

Fahsold R, Hoffmeyer S, Mischung C, et al. (2000) Minor le-
sion mutational spectrum of the entire NF1 gene does not
explain its high mutability but points to a functional domain
upstream of the GAP-related domain. Am J Hum Genet 66:
790–818.

Frommolt P, Abdallah AT, Altmu¨ller J, et al. (2012) Assessing
the enrichment performance in targeted resequencing exper-
iments. Hum Mutat 33:635–641.

Gasparini P, D’Agruma L, Pio de Cillis G, et al. (1996) Scan-
ning the ﬁrst part of the neuroﬁbromatosis type 1 gene by
RNA-SSCP: identiﬁcation of three novel mutations and of
two new polymorphisms. Hum Genet 97:492–495.

Han SS, Cooper DN, Upadhyaya MN (2001) Evaluation of de-
naturing high performance liquid chromatography (DHPLC)
for the mutational analysis of the neuroﬁbromatosis type 1
(NF1) gene. Hum Genet 109:487–497.

Hattori M, Torii C, Yagihashi T, et al. (2009) Diagnosis of
Russell-Silver syndrome by the combined bisulﬁte restriction
analysis—denaturing high-performance liquid chromatogra-
phy assay. Genet Test Mol Biomarkers 13:623–630.

Japanese Genetic Variation Consortium (2013) Human genetic
variation browser. Available at www.genome.med.kyoto-
u.ac.jp/SnpDB (accessed March 18 2014).

Jones K (2005) Smith’s Recognizable Patterns of Human

Malformation. Saunders, Philadelphia.

Kosaki K, Udaka T, Okuyama T (2005) DHPLC in clinical
molecular diagnostic services. Mol Genet Metab 86:117–123.
Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of
coding non-synonymous variants on protein function using
the SIFT algorithm. Nat Protoc 4:1073–1081.

Lee MJ, Su YN, You HL, et al. (2006) Identiﬁcation of forty-
ﬁve novel and twenty-three known NF1 mutations in Chinese
patients with neuroﬁbromatosis type 1. Hum Mutat 27:832.

95% of mutations and reveals a high frequency of unusual
splicing defects. Hum Mutat 15:541–555.

Nemethova M, Bolcekova A, Ilencikova D, et al. (2013) Thirty-
nine novel neuroﬁbromatosis 1 (NF1) gene mutations iden-
tiﬁed in Slovak patients. Ann Hum Genet 77:364–379.

Neuroﬁbromatosis Conference Statement (1988) National In-
stitutes of Health Consensus Development Conference. Arch
Neurol 45:575–578.

Purandare SM, Huntsman Breidenbach H, et al. (1995) Identi-
ﬁcation of neuroﬁbromatosis 1 (NF1) homologous loci by
direct sequencing, ﬂuorescence in situ hybridization, and PCR
ampliﬁcation of somatic cell hybrids. Genomics 30:476–485.
Purandare SM, Lanyon WG, Connor JM (1994) Characterisa-
tion of inherited and sporadic mutations in neuroﬁbromatosis
type-1. Hum Mol Genet 3:1109–1115.

Richards CS, Bale S, Bellissimo DB, et al. (2008) ACMG
recommendations for standards for interpretation and report-
ing of sequence variations: revisions 2007. Genet Med 10:
294–300.

Rozen S, Skaletsky H (2000) Primer3 on the www for general
users and for biologist programmers. Methods Mol Biol
132:365–386.

Sabbagh A, Pasmant E, Imbard A, et al. (2013) NF1 molecular
characterization and neuroﬁbromatosis type I genotype-
phenotype correlation: the French experience. Hum Mutat 34:
1510–1518.

Samejima H, Torii C, Kosaki R, et al. (2007) Screening for
Alagille syndrome mutations in the JAG1 and NOTCH2 genes
using denaturing high-performance liquid chromatography.
Genet Test Mol Biomarkers 11:216–227.

Schwarz JM, Ro¨delsperger C, Schuelke M, et al. (2010) Mu-
tationTaster evaluates disease-causing potential of sequence
alterations. Nat Methods 7:575–576.

Siepel A, Pollard KS, Haussler D (2009) New methods for
detecting lineage-speciﬁc selection. Proceedings of the 10th
International Conference on Research in Computational. Mol
Biol 3909:190–205.

Takenouchi T, Hida M, Sakamoto Y, et al. (2013a) Severe
congenital lipodystrophy and a progeroid appearance: muta-
tion in the penultimate exon of FBN1 causing a recognizable
phenotype. Am J Med Genet A 161A:3057–3062.

Takenouchi T, Matsuzaki Y, Torii C, et al. (2014) SOX9 di-
merization domain mutation mimicking type 2 collagen dis-
order phenotype. Eur J Med Genet 57:298–301.

Takenouchi T, Shimizu A, Torii C, et al. (2013b) Multiple Cafe´
au Lait spots in familial patients with MAP2K2 mutation. Am
J Med Genet A 164A:392–396.

Teer JK, Green ED, Mullikin JC, et al. (2012) VarSifter: vi-
sualizing and analyzing exome-scale sequence variation data
on a desktop computer. Bioinformatics 28:599–600.

Thorvaldsdo´ttir H, Robinson JT, Mesirov JP (2013) Integrative
Genomics Viewer (IGV): high-performance genomics data
visualization and exploration. Brief Bioinform 14:178–192.

Li H, Durbin R (2009) Fast and accurate short read alignment
with Burrows-Wheeler Transform. Bioinformatics 25:1754–
1760.

Udaka T, Imoto I, Aizu Y, et al. (2007) Multiplex PCR/liquid
chromatography assay for screening of subtelomeric re-
arrangements. Genet Test Mol Biomarkers 11:241–248.

Li Y, Bollag G, Clark R, et al. (1992) Somatic mutations in the
neuroﬁbromatosis 1 gene in human tumors. Cell 69:275–281.
McKenna A, Hanna M, Banks E, et al. (2010) The Genome
Analysis Toolkit: a MapReduce framework for analyzing
next-generation DNA sequencing data. Genome Res 20:
1297–1303.

Messiaen LM, Callens T, Mortier G, et al. (2000) Exhaustive
mutation analysis of the NF1 gene allows identiﬁcation of

Udaka T, Kurosawa K, Izumi K, et al. (2006) Screening for
partial deletions in the CREBBP gene in Rubinstein-Taybi
syndrome patients using multiplex PCR/liquid chromatogra-
phy. Genet Test Mol Biomarkers 10:265–271.

Udaka T, Torii C, Takahashi D, et al. (2005) Comprehensive
screening of
the thiopurine methyltransferase polymor-
phisms by denaturing high-performance liquid chromatogra-
phy. Genet Test Mol Biomarkers 9:85–92.

14

Upaddhyaya M (2008) NF1 gene structure and NF1 genotype/
In: Kaufmann D (ed) Neuroﬁ-

phenotype correlations.
bromatoses. Karger, Basel, pp 46–62.

Valero MC, Martı´n Y, Herna´ndez-Imaz E, et al. (2011) A
highly sensitive genetic protocol to detect NF1 mutations.
J Mol Diagn 13:113–122.

Yan D, Tekin M, Blanton SH, et al. (2013) Next-generation
sequencing in genetic hearing loss. Genet Test Mol Bio-
markers 17:581–587.

MARUOKA ET AL.

Address correspondence to:
Kenjiro Kosaki, MD, FACMG
Center for Medical Genetics
Keio University School of Medicine
35 Shinanomachi, Shinjuku-ku
Tokyo 160-8582
Japan

E-mail: kkosaki@z3.keio.jp

